文献速递胸部病理细胞病理与分子病理

ALK重排NSCLC中遗传不稳定性与复发性MYC扩增:TP53突变的中心作用

Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.
PubMed 文献 · J Pathol · 2018-07-31

该研究分析了53例伴或不伴TP53突变的ALK+非小细胞肺癌肿瘤及ALK+细胞系,采用NanoString nCounter技术。发现TP53突变患者中24%出现已知癌症基因扩增,如MYC(14%)、CCND1(10%)等,MYC过表达细胞具有增殖优势,且MYC结合EML4启动子区导致EML4-ALK上调,提示MYC依赖的耐药机制。

要点

  • ALK+ NSCLC中TP53突变与染色体不稳定性相关,可导致MYC等基因扩增。
  • TP53突变患者中24%存在癌症基因扩增,MYC扩增占14%。
  • MYC过表达通过结合EML4启动子上调EML4-ALK,可能介导耐药。

核心结论

  • ALK+ NSCLC中TP53突变定义了一个具有染色体不稳定性和致病性畸变共存的亚群。
  • MYC过表达在ALK+ TP53突变细胞中提供增殖优势并上调EML4-ALK,提示MYC依赖的耐药机制。

研究设计与样本

  • 研究分析了53例伴或不伴TP53突变的ALK+肿瘤及ALK+ NSCLC细胞系,采用NanoString nCounter技术。

主要发现

  • TP53突变患者中24%显示已知癌症基因扩增,包括MYC(14%)、CCND1(10%)、TERT(5%)、BIRC2(5%)、ORAOV1(5%)和YAP1(5%)。
  • MYC过表达的ALK+ TP53突变细胞相比野生型细胞具有增殖优势。
  • ChIP-Seq数据显示MYC结合位点位于EML4启动子区,MYC过表达导致EML4-ALK上调。

关键数值与推荐

  • TP53突变患者中24%存在癌症基因扩增,MYC扩增频率为14%。
  • CCND1扩增频率为10%,TERT、BIRC2、ORAOV1、YAP1扩增频率各为5%。

临床怎么用

  • 在ALK+ NSCLC中检测TP53突变可能有助于识别具有染色体不稳定性和复发风险较高的患者。
  • MYC扩增或过表达可能作为潜在耐药标志物,需进一步验证。

局限性

  • 研究样本量较小(53例肿瘤),需更大队列验证。
  • 机制探索主要基于细胞系和ChIP-Seq数据,临床转化需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The anaplastic lymphoma kinase (ALK) rearrangement defines a distinct molecular subtype of non-small cell lung cancer (NSCLC). Despite the excellent initial efficacy of ALK inhibitors in patients with ALK+ lung cancer, resistance occurs almost inevitably. To date, there is no reliable biomarker allowing the identification of patients at higher risk of relapse. Here, we analysed a subset of 53 ALK+ tumours with and without TP53 mutation and ALK+ NSCLC cell lines by NanoString nCounter technology. We found that the co-occurrence of early TP53 mutations in ALK+ NSCLC can lead to chromosomal instability: 24% of TP53-mutated patients showed amplifications of known cancer genes such as MYC (14%), CCND1 (10%), TERT (5%), BIRC2 (5%), ORAOV1 (5%), and YAP1 (5%). MYC-overexpressing ALK+ TP53-mutated cells had a proliferative advantage compared to wild-type cells. ChIP-Seq data revealed MYC-binding sites within the promoter region of EML4, and MYC overexpression in ALK+ TP53-mutated cells resulted in an upregulation of EML4-ALK, indicating a potential MYC-dependent resistance mechanism in patients with increased MYC copy number. Our study reveals that ALK+ NSCLC represents a more heterogeneous subgroup of tumours than initially thought, and that TP53 mutations in that particular cancer type define a subset of tumours that harbour chromosomal instability, leading to the co-occurrence of pathogenic aberrations. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

来源:J Pathol,查看原文。版权归原作者所有。

引用

  1. Alidousty C, Baar T, Martelotto LG, et al. Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations. J Pathol. 2018. PMID: 29885057. doi:10.1002/path.5110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。